Rice Suspension Cell Recombinant Protein Expression System: Comparison
Please note this is a comparison between Version 2 by Peter Tang and Version 1 by Li-Fen Huang.

A plant cell-based recombinant glucocerebrosidase was approved by the FDA in 2012 for the treatment of human inherited Gaucher disease, indicating that plant suspension cells have advantages in biosafety and a low production cost as a commercial pharmaceutical recombinant protein expression system. A low allergenic rice suspension cell-based recombinant protein expression system controlled by the αAmy3/RAmy3D promoter has been shown to result in relatively high protein yields in plant cell-based systems.

  • αAmy3 promoter
  • recombinant protein
  • rice suspension cell
  • signal peptide

1. Introduction

The production of valuable recombinant proteins in bacteria, yeasts, insect cells, mammalian cells and even plant cells by genetic engineering has become an important and common biotechnology in medical uses, with an estimated market value of approximately USD 400 billion by 2025 [1]. Each type of host cell has its own characteristics; thus, even the same recombinant proteins often show differences in biological activity and stability among various host cell protein expression systems. More than 50% of human proteins and 40% of commercial recombinant pharmaceutical proteins are glycoproteins; therefore, eukaryotic cells are often required as host cells to perform glycosylation for these recombinant proteins to have their best performances [2]. Although the current commercial biosimilars are mostly produced by Chinese hamster ovary (CHO) cells [3], the susceptibility to feedback inhibition of animal host cells limits the production of pharmaceutical recombinant proteins. In addition, production costs by expensive serum or required growth factors and biosafety concerns from common animal pathogens have pushed scientists to seek nonanimal-derived eukaryotic cell expression systems. Plant cells have advantages in protein post-modification, low production cost and high biosafety, and they are therefore applied to produce pharmaceutical recombinant proteins [4,5,6][4][5][6]. Many biopharmaceutical proteins, including antibodies, antigens and therapeutic proteins, have been successfully expressed in plant cells, and some are in clinical trials [7]; therefore, plant cell expression systems have attracted global attention.
Plant suspension cells are commonly cultured in relatively simple and inexpensive liquid medium compared to microbial and animal cells [1,4,5,6,7][1][4][5][6][7]. The recombinant protein can be fused to a signal peptide and then secreted into cell culture liquid medium. Secretory recombinant proteins can be obtained easily without breaking plant host cells, and purification from medium proteins is much easier than purification from cellular proteins. Recombinant protein expression platforms based on suspension cell culture have been generated from several plant species, such as rice, tobacco and carrot. The first plant recombinant pharmaceutical protein, human beta-glucocerebrosidase for Gaucher disease patients, was produced from carrot suspension cells and approved by the FDA in 2012 [8]. This commercial case shows that the plant suspension cell expression system can fit the requirements of GMP and government regulation. It also proves that plant suspension cell expression systems have the potential to compete with the two major commercial protein expression systems, microbial E. coli and mammalian CHO cells.

2. Advantages of Plant Suspension Culture Cells

Among the current well-developed foreign protein expression platforms, plant cells have many advantages compared with microbial fermentation and animal and insect cell culture. Microbial systems perform limited post-translational modification for recombinant genes derived from eukaryotic cells. Recombinant proteins expressed in the E. coli system commonly have incorrect protein folding and form insoluble inclusion bodies. These inclusion bodies require extra solubilization and refolding steps to allow recombinant proteins to fold into the correct structure and therefore increase the protein purification cost [9,10][9][10]. In addition, the cost of recombinant protein production is further increased to completely remove possible endotoxins produced during the bacterial culture process. On the other hand, it is more expensive to produce recombinant proteins in mammalian and insect cells than in plant cells because of artificial culture medium supplemented with a variety of expensive growth factors and cytokines to meet the needs of host cell growth, coupled with cell sensitivity to mechanical stress in the bioreactor [1,4,5,6,7][1][4][5][6][7]. Well-established plant cell culture technology has been applied for the production of valuable metabolites, such as artemisinin, chlorogenic acid and ginsenosides [11,12,13,14][11][12][13][14]. Simons et al. were the first to use potato and tobacco cells to produce medically valuable recombinant human serum albumin in liquid culture medium [15]. Plant cells cultivated in a sterile cell culture environment have more advantages than plants grown in greenhouses or fields. For example, agricultural fertilizers and pesticides are not used in the plant suspension cell culture expression system, and they therefore do not cause environmental pollution. There is no potential transgene contamination in plant suspension cells. In addition, the proliferation rate of plant suspension cells is high as compared to solid cultured cells, and the production time required to obtain recombinant protein is shorter than that of transgenic plants. Compared with the whole plant system, the plant suspension cell system produces recombinant proteins under a controlled aseptic culture environment and therefore improves the biological safety of recombinant proteins [16,17][16][17]. Purification of recombinant proteins remains the major cost of commercial recombinant protein products; thus, protein purification is an expensive and challenging step in the biotechnology industry [18,19][18][19]. Plant suspension cells can easily reduce the cost of recombinant protein purification by fusing the signal peptide sequence with the target gene, and the recombinant protein can be directly secreted into the extracellular culture medium. The strategy simplifies the process of recombinant protein purification by avoiding interference from a large amount of intracellular proteins. Therefore, using plant suspension cells to produce valuable recombinant proteins is a good, economical, safe and simple strategy, with the following advantages: (1) plant cells are eukaryotic, similar to animal cells, and can perform complex post-translational modification; (2) recombinant proteins produced by plants can be expressed in particular subcellular organelles, such as the endoplasmic reticulum, chloroplasts and vacuole [20,21][20][21]; and (3) the recombinant human proteins produced by plants can avoid cross-contamination of human or animal pathogens and have less interference from other family members, which share similar protein structures, to make protein purification easy and safe. Since the first successful case was reported in 1990, recombinant proteins, including medical vaccines, antibodies, cytokines, other protein drugs, industrial enzymes and food additives, have been successfully expressed in plant cells [9,22,23,24,25,26][9][22][23][24][25][26].

3. Rice Suspension Cell Recombinant Protein Expression System

Tobacco and rice cells are commonly used in suspension culture to express recombinant proteins. In general, the constitutively active cauliflower mosaic virus CaMV 35S promoter is used to produce foreign proteins in tobacco cells. The yield of recombinant human antibody in tobacco cells in 200 L bioreactor was approximately 20 mg/L [27], and tobacco cells are known for the production of toxic alkaloids and proteolytic enzymes. On the other hand, the recombinant protein production platform of rice suspension cells generally has a protein yield more than 10 times that of tobacco cells [9]. Rice suspension cell protein expression systems have been established on a large scale to produce various recombinant proteins in several biotech companies, such as Natural Bio-Materials at Korea [28]. Several valuable pharmaceutical recombinant proteins produced from rice cells are under clinical trials, such as Vibrio cholera CTB (cholera toxin B subunit) for cholera [29]. Various growth factors, enzymes, interferons and antibodies have been successfully produced in rice cell suspension culture systems [22,30,31,32,33][22][30][31][32][33]. The recombinant protein expression system of rice suspension cells often uses a transgenic cell line containing the inducible αAmy3 (also called RAmy3D) promoter and its signal peptide to secrete the recombinant protein into the culture medium under sugar starvation conditions [34,35][34][35]. Diagrammatic representation of the rice suspension cell expression system and process for various recombinant protein production under the control of αAmy3 promoter and its signal peptide is shown in Figure 1. Briefly, a gene of interest, which may be modified with codon optimized sequence in rice, is cloned downstream of the αAmy3 promoter-signal peptide sequence either by Gateway or restriction enzyme cloning technology. The high yield of stable transgenic rice cell lines can be screened after an expression cassette is transferred into the rice nucleus by Agrobacterium- or particle bombardment-mediated transformation. αAmy3 is a member of the α-amylase gene family, and rice contains 10 α-amylase genes. When cereal seeds are in the germination stage, α-amylase genes in embryos and aleurone cells begin to express and secrete α-amylase into the endosperm to break down starch into small molecular sugars by cutting the α-1,4 glucose linkage in amylose and amylopectin molecules. The main α-amylase genes expressed in rice suspension cells are αAmy3, αAmy7/RAmy1A and αAmy8/RAmy3E, and their promoters are regulated by gibberellic acid, abscisic acid and carbohydrates. αAmy3 has the highest expression level induced by glucose deficiency among the whole rice α-amylase gene family in rice suspension cells [36], and the expression level can be continuously enhanced for up to 48 h [37]. The signal peptide of αAmy3 can be applied to allow the fusion of recombinant proteins secreted into the extracellular medium to simplify the protein purification steps.
Figure 1. Schematic diagram of the αAmy3 promoter-signal peptide-based recombinant protein production system. The expression vector contained the rice αAmy3 promoter-signal peptide sequence, nos terminator (nosT), and the hygromycin selection marker (Hpt). The αAmy3 promoter-signal peptide-gene of interest expression cassette is transferred into rice nucleus. The recombinant proteins are secreted into sugar-free liquid medium from rice suspension cells under recombinant protein production stage.
The rice suspension cell expression system is divided into two cell culture stages: the cell proliferation stage and the recombinant protein production stage (Figure 1). During the cell proliferation stage, the rice suspension cells are cultured in a liquid medium containing a carbon source, such as sucrose. Rice cells replicate and proliferate, and highly increase the number of rice suspension cells; then, the cell culture medium is replaced with a medium lacking a carbon source to activate the αAmy3 promoter, and the recombinant protein is produced and secreted via the default pathway of the αAmy3 signal peptide into the liquid medium. The advantages of this rice expression system are as follows. (1) An easy tissue culture procedure is enough to establish homogeneous and rapidly growing rice suspension cultured cells. Rice suspension cultured cells have a doubling time of about 2 days [38]. (2) The use of a strong inducible αAmy3 promoter can be easily activated by the absence of sugar in the cell culture medium to express recombinant proteins. (3) The application of secretory signal peptides can be utilized to transport recombinant proteins from the cytosol into the culture medium. After simple collection of the cell culture liquid medium, the recombinant proteins can be purified without breaking the cells. Continuous production of recombinant proteins can be carried out without sacrificing rice host cells. Rice cells can be reused for recombinant protein production, and the sugar feeding and starvation cycle also saves time for cell proliferation.

References

  1. Chung, Y.H.; Church, D.; Koellhoffer, E.C.; Osota, E.; Shukla, S.; Rybicki, E.P.; Pokorski, J.K.; Steinmetz, N.F. Integrating plant molecular farming and materials research for next-generation vaccines. Nat. Rev. Mater. 2021, 7, 372–388.
  2. Rozov, S.M.; Permyakova, N.V.; Deineko, E.V. Main Strategies of Plant Expression System Glycoengineering for Producing Humanized Recombinant Pharmaceutical Proteins. Biochemistry. 2018, 83, 215–232.
  3. Walsh, G. Biopharmaceutical benchmarks 2018. Nat. Biotechnol. 2018, 36, 1136–1145.
  4. Schillberg, S.; Finnern, R. Plant molecular farming for the production of valuable proteins—Critical evaluation of achievements and future challenges. J. Plant Physiol. 2021, 258–259, 153359.
  5. Shanmugaraj, B.; Bulaon, C.J.I.; Phoolcharoen, W. Plant Molecular Farming: A Viable Platform for Recombinant Biopharmaceutical Production. Plants 2020, 9, 842.
  6. Singh, A.A.; Pillay, P.; Tsekoa, T.L. Engineering Approaches in Plant Molecular Farming for Global Health. Vaccines 2021, 9, 1270.
  7. Ghag, S.B.; Adki, V.S.; Ganapathi, T.R.; Bapat, V.A. Plant Platforms for Efficient Heterologous Protein Production. Biotechnol. Bioprocess Eng. 2021, 26, 546–567.
  8. Shaaltiel, Y.; Bartfeld, D.; Hashmueli, S.; Baum, G.; Brill-Almon, E.; Galili, G.; Dym, O.; Boldin-Adamsky, S.A.; Silman, I.; Sussman, J.L.; et al. Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher’s disease using a plant cell system. Plant Biotechnol. J. 2007, 5, 579–590.
  9. Kuo, Y.C.; Tan, C.C.; Ku, J.T.; Hsu, W.C.; Su, S.C.; Lu, C.A.; Huang, L.F. Improving pharmaceutical protein production in Oryza sativa. Int. J. Mol. Sci. 2013, 14, 8719–8739.
  10. Singhvi, P.; Panda, A.K. Solubilization and Refolding of Inclusion Body Proteins. Methods Mol. Biol. 2022, 2406, 371–387.
  11. Wawrosch, C.; Zotchev, S.B. Production of bioactive plant secondary metabolites through in vitro technologies-status and outlook. Appl. Microbiol. Biotechnol. 2021, 105, 6649–6668.
  12. Biswas, T.; Pandey, S.S.; Maji, D.; Gupta, V.; Kalra, A.; Singh, M.; Mathur, A.; Mathur, A.K. Enhanced expression of ginsenoside biosynthetic genes and in vitro ginsenoside production in elicited Panax sikkimensis (Ban) cell suspensions. Protoplasma 2018, 255, 1147–1160.
  13. Zebarjadi, A.; Dianatkhah, S.; Pour Mohammadi, P.; Qaderi, A. Influence of abiotic elicitors on improvement production of artemisinin in cell culture of Artemisia annua L. Cell. Mol. Biol. 2018, 64, 1–5.
  14. Liu, Z.-B.; Chen, J.-G.; Yin, Z.-P.; Shangguan, X.-C.; Peng, D.-Y.; Lu, T.; Lin, P. Methyl jasmonate and salicylic acid elicitation increase content and yield of chlorogenic acid and its derivatives in Gardenia jasminoides cell suspension cultures. Plant Cell Tissue Organ Cult. 2018, 134, 79–93.
  15. Sijmons, P.C.; Dekker, B.M.; Schrammeijer, B.; Verwoerd, T.C.; van den Elzen, P.J.; Hoekema, A. Production of correctly processed human serum albumin in transgenic plants. Biotechnology 1990, 8, 217–221.
  16. Schillberg, S.; Raven, N.; Fischer, R.; Twyman, R.M.; Schiermeyer, A. Molecular farming of pharmaceutical proteins using plant suspension cell and tissue cultures. Curr. Pharm. Des. 2013, 19, 5531–5542.
  17. Fischer, R.; Emans, N. Molecular farming of pharmaceutical proteins. Transgenic Res. 2000, 9, 279–299, Discussion 277.
  18. Kusnadi, A.R.; Nikolov, Z.L.; Howard, J.A. Production of recombinant proteins in transgenic plants: Practical considerations. Biotechnol. Bioeng. 1997, 56, 473–484.
  19. Mir-Artigues, P.; Twyman, R.M.; Alvarez, D.; Cerda Bennasser, P.; Balcells, M.; Christou, P.; Capell, T. A simplified techno-economic model for the molecular pharming of antibodies. Biotechnol. Bioeng. 2019, 116, 2526–2539.
  20. Staub, J.M.; Garcia, B.; Graves, J.; Hajdukiewicz, P.T.; Hunter, P.; Nehra, N.; Paradkar, V.; Schlittler, M.; Carroll, J.A.; Spatola, L.; et al. High-yield production of a human therapeutic protein in tobacco chloroplasts. Nat. Biotechnol. 2000, 18, 333–338.
  21. Michoux, F.; Ahmad, N.; McCarthy, J.; Nixon, P.J. Contained and high-level production of recombinant protein in plant chloroplasts using a temporary immersion bioreactor. Plant Biotechnol. J. 2011, 9, 575–584.
  22. Chung, N.D.; Kim, N.S.; Giap do, V.; Jang, S.H.; Oh, S.M.; Jang, S.H.; Kim, T.G.; Jang, Y.S.; Yang, M.S. Production of functional human vascular endothelial growth factor(165) in transgenic rice cell suspension cultures. Enzyme Microb. Technol. 2014, 63, 58–63.
  23. Kwon, T.H.; Seo, J.E.; Kim, J.; Lee, J.H.; Jang, Y.S.; Yang, M.S. Expression and secretion of the heterodimeric protein interleukin-12 in plant cell suspension culture. Biotechnol. Bioeng. 2003, 81, 870–875.
  24. Sunil Kumar, G.B.; Ganapathi, T.R.; Revathi, C.J.; Prasad, K.S.; Bapat, V.A. Expression of hepatitis B surface antigen in tobacco cell suspension cultures. Protein Expr. Purif. 2003, 32, 10–17.
  25. Lienard, D.; Sourrouille, C.; Gomord, V.; Faye, L. Pharming and transgenic plants. Biotechnol. Annu. Rev. 2007, 13, 115–147.
  26. Tuse, D.; Tu, T.; McDonald, K.A. Manufacturing economics of plant-made biologics: Case studies in therapeutic and industrial enzymes. Biomed. Res. Int. 2014, 2014, 256135.
  27. Raven, N.; Rasche, S.; Kuehn, C.; Anderlei, T.; Klockner, W.; Schuster, F.; Henquet, M.; Bosch, D.; Buchs, J.; Fischer, R.; et al. Scaled-up manufacturing of recombinant antibodies produced by plant cells in a 200-L orbitally-shaken disposable bioreactor. Biotechnol. Bioeng. 2015, 112, 308–321.
  28. Moon, K.B.; Park, J.S.; Park, Y.I.; Song, I.J.; Lee, H.J.; Cho, H.S.; Jeon, J.H.; Kim, H.S. Development of Systems for the Production of Plant-Derived Biopharmaceuticals. Plants 2019, 9, 30.
  29. Nochi, T.; Takagi, H.; Yuki, Y.; Yang, L.; Masumura, T.; Mejima, M.; Nakanishi, U.; Matsumura, A.; Uozumi, A.; Hiroi, T.; et al. Rice-based mucosal vaccine as a global strategy for cold-chain- and needle-free vaccination. Proc. Natl. Acad. Sci. USA 2007, 104, 10986–10991.
  30. Nam, H.J.; Kwon, J.Y.; Choi, H.Y.; Kang, S.H.; Jung, H.S.; Kim, D.I. Production and Purification of Recombinant Glucocerebrosidase in Transgenic Rice Cell Suspension Cultures. Appl. Biochem. Biotechnol. 2017, 181, 1401–1415.
  31. Chen, T.L.; Lin, Y.L.; Lee, Y.L.; Yang, N.S.; Chan, M.T. Expression of bioactive human interferon-gamma in transgenic rice cell suspension cultures. Transgenic Res. 2004, 13, 499–510.
  32. Hong, S.Y.; Lee, T.S.; Kim, J.; Jung, J.H.; Choi, C.W.; Kim, T.G.; Kwon, T.H.; Jang, Y.S.; Yang, M.S. Tumor targeting of humanized fragment antibody secreted from transgenic rice cell suspension culture. Plant Mol. Biol. 2008, 68, 413–422.
  33. Islam, M.R.; Kim, N.S.; Jung, J.W.; Kim, H.B.; Han, S.C.; Yang, M.S. Spontaneous pepsin C-catalyzed activation of human pepsinogen C in transgenic rice cell suspension culture: Production and characterization of human pepsin C. Enzyme Microb. Technol. 2018, 108, 66–73.
  34. Yu, S.M.; Kuo, Y.H.; Sheu, G.; Sheu, Y.J.; Liu, L.F. Metabolic derepression of alpha-amylase gene expression in suspension-cultured cells of rice. J. Biol. Chem. 1991, 266, 21131–21137.
  35. Huang, N.; Chandler, J.; Thomas, B.R.; Koizumi, N.; Rodriguez, R.L. Metabolic regulation of alpha-amylase gene expression in transgenic cell cultures of rice (Oryza sativa L.). Plant Mol. Biol. 1993, 23, 737–747.
  36. Yu, S.M.; Tzou, W.S.; Lo, W.S.; Kuo, Y.H.; Lee, H.T.; Wu, R. Regulation of alpha-amylase-encoding gene expression in germinating seeds and cultured cells of rice. Gene 1992, 122, 247–253.
  37. Ho, S.; Chao, Y.; Tong, W.; Yu, S. Sugar coordinately and differentially regulates growth- and stress-related gene expression via a complex signal transduction network and multiple control mechanisms. Plant Physiol. 2001, 125, 877–890.
  38. Santos, R.B.; Abranches, R.; Fischer, R.; Sack, M.; Holland, T. Putting the Spotlight Back on Plant Suspension Cultures. Front. Plant Sci. 2016, 7, 297.
More